Sector News

Daiichi Sankyo makes another big whack at U.S. sales operations

March 6, 2018
Life sciences

Daiichi Sankyo, which has struggled financially since losing exclusivity for its blood pressure drug Benicar, is again swinging the job-cutting ax in the U.S., cutting 280 jobs from its commercial operations.

The Japanese drugmaker last week said the jobs are being eliminated from various locations in the U.S., as it streamlines its business to fit its current U.S. portfolio and “prepare for its upcoming oncology pipeline.”

“Our priorities are to bring spending in line with revenue, shift resources to maximize Injectafer and our abuse-deterrent pain treatments, and prepare for exciting potential new treatments for patients with cancer being developed by our R&D organization,” Ken Keller, president of administrative and commercial for Daiichi Sankyo, said in a statement.

The cuts follow a downsizing of about 1,200 employees in the U.S. which culminated with the company melding its U.S. R&D and commercial operations in a new facility in Basking Ridge, New Jersey, in April 2016. About 700 employees from its former U.S. headquarters in Parsippany, New Jersey, and R&D in Edison, New Jersey, made that move.

Daiichi also closed a 170-person R&D facility in India last year and month later shuttered another in Japan with 150 employees.

Daiichi has been trying to remake itself since before losing patent protection on its $2.6 billion seller Benicar in 2016. It has been shifting away from primary care meds and toward specialty drugs such as its clot-fighting pill Savaysa, and Movantik, a constipation drug it markets with AstraZeneca.

Last year it also had to lay out $300 million to settle about 2,300 lawsuits tied to side effects of the blood pressure medication and several related drugs.

By Eric Palmer

Source: Fierce Pharma

comments closed

Related News

December 3, 2023

FDA names chief scientist Bumpus as Woodcock’s successor

Life sciences

The Food and Drug Administration’s top scientist Namandjé Bumpus will assume the role of principal deputy commissioner when longtime agency leader Janet Woodcock retires from that role in early 2024, according to an announcement Thursday.

December 3, 2023

AbbVie to buy cancer drug maker ImmunoGen for $10.1 Billion

Life sciences

US biopharma AbbVie has agreed to acquire ImmunoGen in a deal which values the company at about $10.1 billion and gives AbbVie access to flagship cancer therapy Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC), as well as a pipeline of promising next-generation ADCs.

December 3, 2023

EuroAPI appoints new Executive Committee members

Life sciences

EUROAPI today announced the appointment of David Seignolle as Chief Operating Officer, succeeding Eric Berger, and Marion Santin as Chief Legal, Compliance, and IP Officer, both joining the company’s Executive Committee. In his new role, David Seignolle will lead the transformation of the Industrial Operations organization.

How can we help you?

We're easy to reach